Amoéba: Promising Trials in Brazil Pave the Way for the Soy Market
Amoéba (FR0011051598 - ALMIB) announces that it has conducted a comprehensive field testing program in Brazil, in partnership with Koppert, to evaluate the potential of its AXPERA biofungicide technology on soybeans and orange trees, two strategic crops for the country.
The trials conducted in Brazil are part of the strategic agreement signed with Koppert in June 2025. A visit at the end of March demonstrated the promising nature of the trials and confirmed the Brazilian market's interest in Amoéba. The AXPERA technology complements the European and American markets where the two companies focus on vineyards and vegetable crops.
Significant Results in Soy and Orange Crops
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Regarding soy, which covers about 48 million hectares in Brazil, the testing program confirmed AXPERA's promising performance against Asian rust, tested under real agricultural conditions in addition to a standard fungicide program. For orange trees, which cover about 450,000 hectares, the initial results observed against bacterial canker seem encouraging and could contribute to reducing the use of copper.
Potential Commercialization and Regulatory Steps
Amoéba is considering the potential commercialization of its technology in Brazil by 2028. The next steps include obtaining approval from Brazilian authorities, with approval expected in 2027 for the first use against soy rust. The Ministry of Health has already confirmed the non-hazardous nature of the AXPERA product. A new trial campaign will be carried out in 2027 in other regions representative of soy and orange crops for a final confirmation of the marketing positioning.
Sur la base de ses ressources actuelles, de son plan d'affaires et de la lettre de soutien de son actionnaire de référence, Amoéba estime pouvoir faire face à ses obligations jusqu'au 31 décembre 2026.
Risks mentioned
Autorisation définitive d'AXPERA obtenue tardivement (fin juin 2026) après période d'utilisation des produits, affectant les ventes du semestre
Monétisation de la plateforme cosmétique dont ni la réalisation, ni le calendrier, ni le montant ne sont acquis à ce jour
Besoin de levée de fonds supplémentaire pour assurer continuité d'exploitation jusqu'au 30 septembre 2027 et financer plan de développement
Opportunities identified
Autorisation pérenne AXPERA obtenue en France en juin 2026 ouvre la voie à la commercialisation en plusieurs pays européens
Accord majeur signé avec Syngenta pour distribution exclusive de la solution en céréales dans 27 pays UE, premiers lancements commerciaux attendus Q3 2028
Extension de l'accord de distribution Koppert jusqu'en juin 2031 et potentiel de monétisation de la plateforme cosmétique Willa™ dès 2027
Outlook / guidance
Expected revenue: 1,5 millions d'euros
Management commentary: Building on the outcomes of the various strategic initiatives undertaken since 2023, Amoéba will be able to leverage the ramp-up of its contracts in the agricultural sector from 2027 onwards to achieve revenue of between €1 million and €2 million.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
